A.1. Refereed Publications

(a) MANUSCRIPTS


139. Remington G, Shammi C. Overstating the case about recovery? (ltr) Psych Serv 56:1022, 2005


166. Remington G. What do animal models tell us about physical and mental health (Commentary)? Mental Health and Physical Activity 2:10-15, 2009

scores: comparison of strategies for quantitative trait haplotype analysis.
Schizophr Res 110:200-201, 2009


176. Foussias G, Remington G. Negative symptoms in schizophrenia: multidimensional or Occam’s razor? Schizophr Bull, 36:359-369, 2010


236. Takeuchi H, Remington G. A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology 228:175-185, 2013


matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophr Bull 41:85-93, 2015


328. Fervaha G, Duncan M, Foussias G, Agid O, Faulkner GE, Remington G. Effort-based decision making as an objective paradigm for the assessment of motivational deficits in schizophrenia. Schizophr Res 2015 July 4 [Epub ahead of print]


(b) PUBLISHED REVIEWS OF MANUSCRIPTS


A.2. Non-Refereed Publications

(a) CHAPTERS


(b) BOOKS


(c) BOOK REVIEWS


(d) OTHER REVIEWS/REPORTS/CONSENSUS GUIDELINES

1. Remington G. Zotepine was as effective as typical and other atypical antipsychotics and more effective than schizophrenia in schizophrenia (commentary). Evid Based Ment Health, 3:78, 2000

2. Remington G. Intramuscular ziprasidone reduced symptoms and was well tolerated in acute psychosis (commentary). Evid Based Ment Health, 4:74, 2001

3. Remington G, Kapur S. Amisulpride is effective and safe in schizophrenia (commentary). Evid Based Ment Health, 5:85, 2002


(e) GOVERNMENT REPORTS

1. Atypical antipsychotics for schizophrenia: combination therapy and high doses [Internet]. Ontarion (ON). Canadian Agency for Drugs and Technologies in Health; 2011 Dec.


(f) PUBLISHED ABSTRACTS


29. Kapur S, Seeman P, Zipursky RB, Remington GJ. Fast dissociation from the dopamine D2 receptor (not high affinity at multiple receptors) is the key to “atypical” antipsychotics. Schizophr Res 49(suppl):92, 2001


46. Jensen J, McIntosh R, Crawley AP, Mikulis DJ, Remington G, Kapur S. An fMRI paradigm to study responses to aversive stimuli – a central role for limbic striatum. Schizophr Res 2003; 60 (suppl): 224


49. Collins A, Remington GJ. An educational intervention designed to improve treatment adherence in schizophrenia. Schizophr Res 2003; 60 (suppl): 321


64. Collins A, Remington G. An educational intervention designed to improve treatment adherence in first-episode schizophrenia. Schizophr Res 2004; 70(suppl): 92

65. Cohn TA, Wolever T, Bois D, Zipursky RB, Remington G. First episode and neuroleptic free patients with schizophrenia have reduced insulin sensitivity: a minimal model analysis. Schizophr Bull 2005; 31: 197-198


70. Collins AA, Remington GJ. An educational intervention designed to improve treatment adherence in schizophrenia. Schizophr Bull 2005; 31: 522-523
71. Faulkner GE, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia. Schizophr Bull 2005; 31: 523-524


85. Zai CC, Renou J, De Luca V, Mueller DJ, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Le Foll B, Kennedy JL. Association of brain derived growth factor (BDNF) and dopamine receptor DRD3 gene polymorphisms, as well as their interaction in schizophrenia patients and tardive dyskinesia. Biol Psychiatry 2007; 61(8S): 188S


106. Menon M, Caravaggio F, Graff A, Mamo DC, Remington G. The effects of oxytocin on brain activity during a “trust game” in schizophrenia. Schizophr Bull 2011; Suppl 1: 146-147

108. Foussias G, Mann S, Zakzanis KK, van Reekum, Agid O, Remington G. Baseline motivational deficits as the key predictor of functioning in schizophrenia at 1-year follow-up. Schizophr Bull 2011; Suppl 1:265


114. Schizophr Bull 2011; Suppl 1: 294


(f) OTHER PUBLICATIONS